Both PRSS3 and PRSS22 showed a strong highly significant positive correlation with all seven biomarkers with r-values ranging from 0.2-0.5 for LNs of stage III and 0.5-0.9 for Stage IV patients indicating that these biomarkers are probably expressed by the same population of tumor cells. This evidence concerns the gene PRSS3 and neoplasm.